Willow Biosciences Inc
Atlas Energy Corp., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. The company was formerly known as Willow Biosciences … Read more
Willow Biosciences Inc (CANSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.041x
Based on the latest financial reports, Willow Biosciences Inc (CANSF) has a cash flow conversion efficiency ratio of -0.041x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.15 Million) by net assets ($27.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Willow Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Willow Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Willow Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Willow Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amtel Holdings Bhd
KLSE:7031
|
0.083x |
|
Ralco Corporation Bhd
KLSE:7498
|
0.015x |
|
Trimitra Propertindo Tbk PT
JK:LAND
|
-0.028x |
|
PMC LABEL MATERIALS PUBLIC COMPANY LIMITED
BK:PMC
|
N/A |
|
UPAY Inc
OTCQB:UPYY
|
0.145x |
|
Sanwil Holding SA
WAR:SNW
|
0.005x |
|
4Front Ventures Corp
OTCQX:FFNTF
|
0.031x |
|
Enablence Technologies Inc
PINK:ENAFF
|
0.109x |
Annual Cash Flow Conversion Efficiency for Willow Biosciences Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Willow Biosciences Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-505.00K | $-3.72 Million | 7.372x | +330.62% |
| 2023-12-31 | $3.44 Million | $-10.98 Million | -3.197x | -277.60% |
| 2022-12-31 | $16.37 Million | $-13.86 Million | -0.847x | -37.86% |
| 2021-12-31 | $29.68 Million | $-18.23 Million | -0.614x | -102.69% |
| 2020-12-31 | $-559.00K | $-12.78 Million | 22.862x | +5591.94% |
| 2019-12-31 | $22.01 Million | $-9.16 Million | -0.416x | +73.92% |
| 2018-12-31 | $835.03K | $-1.33 Million | -1.596x | -140.57% |
| 2017-12-31 | $-145.01K | $-570.63K | 3.935x | +49.34% |
| 2016-12-31 | $-383.33K | $-1.01 Million | 2.635x | +712.12% |
| 2016-06-30 | $1.01 Million | $-433.34K | -0.430x | +89.43% |
| 2015-12-31 | $1.10 Million | $-4.48 Million | -4.071x | -815.72% |
| 2014-12-31 | $1.11 Million | $-491.84K | -0.445x | +30.69% |
| 2013-12-31 | $1.35 Million | $-863.26K | -0.641x | -- |
| 2012-12-31 | $858.34K | $0.00 | 0.000x | -- |
| 2011-12-31 | $2.49 Million | $0.00 | 0.000x | -- |
| 2010-12-31 | $3.66 Million | $0.00 | 0.000x | -- |
| 2009-12-31 | $4.92 Million | $0.00 | 0.000x | -- |
| 2008-12-31 | $2.99 Million | $0.00 | 0.000x | -- |